Dendritic cell-tumor cell fusion vaccines.
Publication
, Chapter
Lee, WT
2011
The use of cell fusion has been applied to the development of immunotherapy cancer vaccines. This has typically involved the fusion of dendritic cells and tumor cells. The resultant hybrid uses the specialized antigen presentation properties supplied by the dendritic cell fusion partner to present tumor antigens, both known and yet undefined, to the immune system. This chapter critically examines the scientific foundation of this approach mainly focusing on studies over the last decade. This will include basic principles of tumor fusion vaccines, summary of pre-clinical and clinical data, concluding with remaining challenges and directions.
Duke Scholars
DOI
Publication Date
2011
Volume
713
Start / End Page
177 / 186
Related Subject Headings
- Neoplasms
- Immunotherapy
- General & Internal Medicine
- Dendritic Cells
- Cell Fusion
- Cancer Vaccines
- Antigens, Neoplasm
- 32 Biomedical and clinical sciences
- 31 Biological sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lee, W. T. (2011). Dendritic cell-tumor cell fusion vaccines. (Vol. 713, pp. 177–186). https://doi.org/10.1007/978-94-007-0763-4_11
Lee, Walter T. “Dendritic cell-tumor cell fusion vaccines.,” 713:177–86, 2011. https://doi.org/10.1007/978-94-007-0763-4_11.
Lee WT. Dendritic cell-tumor cell fusion vaccines. In 2011. p. 177–86.
Lee, Walter T. Dendritic cell-tumor cell fusion vaccines. Vol. 713, 2011, pp. 177–86. Pubmed, doi:10.1007/978-94-007-0763-4_11.
Lee WT. Dendritic cell-tumor cell fusion vaccines. 2011. p. 177–186.
DOI
Publication Date
2011
Volume
713
Start / End Page
177 / 186
Related Subject Headings
- Neoplasms
- Immunotherapy
- General & Internal Medicine
- Dendritic Cells
- Cell Fusion
- Cancer Vaccines
- Antigens, Neoplasm
- 32 Biomedical and clinical sciences
- 31 Biological sciences
- 11 Medical and Health Sciences